How Long Can A Dog Live With Atrial Fibrillation: Insights And Expectations

In a study focused on dogs with atrial fibrillation (AFib), researchers observed a group of 64 dogs over time. Of these, 33 dogs either presented with AFib or developed it during follow-up examinations, while the remaining 31 dogs remained free of AFib until they experienced cardiac-related deaths. The study found that dogs with AFib had a median survival time (MST) of 142 days, with a range spanning from 9 to 478 days. In contrast, dogs that did not develop AFib during the study lived longer, with a median survival time of 234 days and a range of 13 to 879 days. This data helps shed light on the expected lifespans of dogs with and without AFib, offering valuable insights for pet owners and veterinarians concerned about this condition’s impact on canine longevity.

Is it possible to cure atrial fibrillation in dogs? Cardioversion, a procedure that aims to restore a normal heart rhythm, can sometimes be effective in dogs. However, it’s important to note that in many cases, the heart may return to atrial fibrillation after cardioversion. Therefore, the treatment for atrial fibrillation in dogs primarily involves the use of medication to control the heart rate. Veterinarians typically prescribe medications such as diltiazem, atenolol, and digoxin to manage the condition and ensure that the dog’s heart rate remains within a healthy range. While atrial fibrillation may not always be completely cured in dogs, these treatments help improve their quality of life and manage the condition effectively.

Is atrial fibrillation (AF) linked to a decrease in life expectancy? Yes, AF has been linked to a potential decrease in life expectancy, primarily due to an increased risk of stroke and heart failure. However, it’s important to note that with advancements in modern medical treatments and interventions, many patients with AF can lead lives that are largely indistinguishable from those without the condition. These treatments have significantly improved the outlook for individuals with AF, mitigating some of the associated health risks and enabling them to enjoy a normal quality of life.